3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
6
Completed
4
Terminated
2
Recruiting
2
Unknown
1
No longer available
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
9
OTHER
2
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Breast Neoplasms
723
Neoplasms
461
Prostatic Neoplasms
398
Carcinoma, Non-Small-Cell Lung
388
Lung Neoplasms
311
Leukemia, Myeloid, Acute
301
Multiple Myeloma
270
Colorectal Neoplasms
243
Neoplasm Metastasis
240
Pancreatic Neoplasms
238
Leukemia
235
Melanoma
217
Lymphoma
213
Precursor Cell Lymphoblastic Leukemia-Lymphoma
204
Brain Neoplasms
195
Recurrence
178
Head and Neck Neoplasms
177
Lymphoma, Non-Hodgkin
174
Myelodysplastic Syndromes
168
Leukemia, Lymphocytic, Chronic, B-Cell
168
Ovarian Neoplasms
160
Carcinoma, Hepatocellular
154
Glioblastoma
149
Carcinoma, Renal Cell
137
Rectal Neoplasms
134
Colonic Neoplasms
129
Lymphoma, Large B-Cell, Diffuse
125
Lymphoma, Follicular
125
Hodgkin Disease
116
Squamous Cell Carcinoma of Head and Neck
109
Interventions
ibritumomab tiuxetan
1
Rituximab
1
Melphalan
1
Etoposide
1
Cytarabine
1
Carmustine
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
OTHER
×
Lymphatic Diseases
×
Clear all
NCT02499627
2021-05-27
FIL-BBV
Fondazione Italiana Linfomi - ETS
Phase 2
Terminated
43 enrolled
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts